CERE
Charles Schwab’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-522,930
| Closed | -$21.4M | – | 3644 |
|
|
2024
Q2 | $21.4M | Sell |
522,930
-142,901
| -21% | -$5.84M | ﹤0.01% | 1637 |
|
|
2024
Q1 | $28.1M | Buy |
665,831
+16,498
| +3% | +$697K | 0.01% | 1412 |
|
|
2023
Q4 | $27.5M | Buy |
649,333
+132,089
| +26% | +$5.6M | 0.01% | 1387 |
|
|
2023
Q3 | $11.3M | Buy |
517,244
+15,261
| +3% | +$333K | ﹤0.01% | 1847 |
|
|
2023
Q2 | $16M | Buy |
501,983
+15,000
| +3% | +$477K | ﹤0.01% | 1648 |
|
|
2023
Q1 | $11.9M | Buy |
486,983
+1,639
| +0.3% | +$40K | ﹤0.01% | 1788 |
|
|
2022
Q4 | $15.3M | Buy |
485,344
+17,558
| +4% | +$554K | ﹤0.01% | 1613 |
|
|
2022
Q3 | $13.2M | Buy |
467,786
+72,301
| +18% | +$2.04M | ﹤0.01% | 1662 |
|
|
2022
Q2 | $10.5M | Buy |
395,485
+22,924
| +6% | +$606K | ﹤0.01% | 1818 |
|
|
2022
Q1 | $13M | Buy |
372,561
+9,441
| +3% | +$331K | ﹤0.01% | 1802 |
|
|
2021
Q4 | $11.8M | Buy |
363,120
+11,312
| +3% | +$367K | ﹤0.01% | 1920 |
|
|
2021
Q3 | $10.4M | Buy |
351,808
+100,315
| +40% | +$2.96M | ﹤0.01% | 1986 |
|
|
2021
Q2 | $6.44M | Buy |
251,493
+79,823
| +46% | +$2.05M | ﹤0.01% | 2221 |
|
|
2021
Q1 | $2.36M | Buy |
171,670
+4,960
| +3% | +$68.1K | ﹤0.01% | 2615 |
|
|
2020
Q4 | $2.77M | Buy |
+166,710
| New | +$2.77M | ﹤0.01% | 2498 |
|